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REVIEW
NONINVASIVE DETECTION OF CORONARY ARTERY
DISEASE - CHALLENGES FOR PREVENTION OF
DISEASE AND CLINICAL EVENTS
Protásio Lemos da Luz, Paulo José Bertini, and Desiderio Favarato
Luz PL da, Bertini PJ, Favarat D. Noninvasive detection of coronary artery disease - challenges for prevention of disease
and clinical events. Clinics. 2005;60(5):415-28.
Atherosclerosis is a chronic inflammatory disease that affects essentially all arterial beds including the aorta, coronaries, carotids,
and peripheral arteries. It is the main cause of death in the western hemisphere, due to cardiovascular syndromes such as myocardial
infarction, heart failure, and cerebrovascular accidents.
Very substantial economic and human resources have been used on treatments of its complications, including imaging studies,
coronary bypass surgery, catheter interventions, pacemakers, and medical treatments. Treating complications, however, are remedial
actions.
A better alternative is to prevent the development of atherosclerosis, or at least to identify patients who are at risk of acute events
and intervene before they occur.
The aims of this review are to discuss the predictive value of traditional and emerging risk factors, as well as the role of noninvasive
diagnostic methods for coronary atherosclerosis, including exercise stress test, echo stress test, duplex ultrasound, computed
tomography, and magnetic resonance.
A combination of serum biomarkers and noninvasive approaches is of practical utility for identifying early disease. It is to be
expected that future developments will  soon perfect our ability to identify the vulnerable patient and allow a more individualized
approach.
KEYWORDS: Atherosclerosis. Lipids. Coronary disease.  Diagnostic tests. Diagnostic imaging, cardiovascular.
Atherosclerosis is a chronic inflammatory disease that
affects essentially all arterial beds including the thoracic
and abdominal aorta, coronary arteries, carotids, peripheral,
renal and mesenteric arteries. It results from a complex in-
teraction between genetic and environmental factors that
causes the arterial wall to respond to inflammatory stimuli
through the actions of endothelial cells, smooth muscle
cells, inflammatory cells, and platelets.1 These produce a
large variety of substances  such as  growth factors,
cytokines, reactive oxygen species, enzymes, signaling fac-
tors  that profoundly alter the arterial wall structure, and
finally lead to the development of the atherosclerotic
plaque.2-4 The plaque is composed of varying amounts of
smooth muscle cells; monocyte-derived macrophages; T
lymphocytes; cholesterol; cholesteryl esters; phospholipids;
and extracellular connective tissue. This ensemble forms
the extracellular matrix including collagen, proteoglycans,
and the pericellular matrix formed by fibronectin and elas-
tic fibers.5-7 The plaque eventually progresses to the point
of  obstructing the arterial lumen, reducing blood flow, and
causing several clinical manifestations. A detailed descrip-
tion of plaque formation and evolution is beyond the scope
of this article.
Atherosclerotic cardiovascular disease is the main cause
of death in the western hemisphere, including in Brazil.8
For the last decades, the principal focus of treatment and
investigation has been its complications, notably myocar-
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dial infarction, angina, sudden death, and heart failure. Very
substantial economic and human resources, including
imaging studies, catheterizations, coronary bypass surgery,
catheter interventions, pacemakers, and medical treatments,
have been used for the diagnosis and treatment of these
complications. In spite of undeniable progress in all these
areas with improved overall outcomes, treating complica-
tions of a disease is in fact a medical failure; we are act-
ing after the events     A better alternative would be to pre-
vent the development of the basic disease, i.e., atheroscle-
rosis, or at least to identify those patients who are at risk
of an acute event and to intervene before damage occurs
†for instance, ahead of the left ventricular dysfunction that
follows a myocardial infarction.
Identifying causative factors of the primary disease is
the fundamental principle of so-called primary prevention.
The rational basis for the application of the principle lies
in the ability to recognize individuals who are at risk for
development of the disease, as well as those who are at risk
for complications; the logical consequence is the custom-
ized use of effective therapeutic approaches.
In order to apply such a preventive approach, a basic
knowledge of the nature of atherosclerosis is essential.
Therefore, some pertinent features of atherosclerosis rel-
evant to its prevention shall be highlighted.
First, atherosclerosis begins very early in life. In fact,
in some instances the genetic determinants of atheroscle-
rosis are present from the moment the ovum is fertilized
by a spermatozoid, and the genes of the parents are mutu-
ally influenced, composing a new human being. However,
this is the fate of a minority; it is estimated that only about
20% of cases of atherosclerosis are genetically deter-
mined.9,10  That atherosclerosis appears in infants, adoles-
cents, and young adults, both male and females, blacks and
whites, has been documented in several necropsy studies
of young persons who died of violent death due to war
wounds, accidents, suicides, or homicides.11-15 These indi-
viduals were asymptomatic, and their mean age was less
than 30 years. In the Bogalusa study,13 the degree of athero-
sclerosis involvement in the aorta and the coronary arter-
ies was directly proportional to the presence of classic risk
factors. Thus, the development of atherosclerosis is an early
phenomenon in humans although its clinical manifestation
may only occur decades later.
Second, the development of atherosclerotic plaques be-
gins in the arterial wall and progresses slowly in such way
that for a long period of time the arterial lumen in not sig-
nificantly affected; consequently blood flow may be normal
even under conditions of increased oxygen demand, such as
intense exercise. Hence no ischemic symptoms may occur.
This was initially documented by Glagov et al16 and termed
positive arterial remodeling; in the initial phases of plaque
formation there is a thickening of the arterial wall and ex-
ternal expansion with maintenance of the lumen. In this
phase, conventional coronary arteriography shows no lumi-
nal abnormalities or only arterial irregularities. For a certain
time in the past, this finding was thought to indicate absence
of atherosclerosis; we now know that is not so. Arterial
remodeling explains the long asymptomatic period so often
seen in patients with coronary artery disease.
Third, lesions that are not hemodynamically significant,
e.g., those causing < 70% stenosis, may suddenly become
unstable, suffer rupture, and cause partial or total occlu-
sions precipitating an acute coronary crisis.17  Many fac-
tors may contribute to this phenomenon, including struc-
tural characteristics of the plaque, endothelial erosions, in-
flammation, and thrombosis.18 Therefore, having a plaque
that is not flow-limiting does not necessary guarantee an
event-free clinical course. This is corroborated by the find-
ing that clinical coronary events are acute in two thirds of
cases, while stable angina represents only one third. In ad-
dition, in 65% of acute coronary syndrome cases
angiographic studies have documented  previous lesions or
the residual lesion in the culprit vessel which were less than
50%.19 The frequency of the destabilization phenomenon,
as well as the fact that interventions such as coronary sur-
gery or angioplasty are usually associated with higher com-
plication rates than elective ones, highlights the importance
of identifying patients with potentially unstable syndromes.
Ideally all interventions should be elective.
Fourth, about 40% of patients in the fifth decade of their
lives with documented coronary artery disease do not have
classic risk factors.20 Therefore, on one hand, the presence
of classic risk factors does confer a greater risk of athero-
sclerosis; on the other, their absence is no guarantee that
the disease will not be present. More recent understanding
of the pathophysiology of atherosclerosis has shed some
light into this question; thus, the inclusion of inflamma-
tion, oxidative stress, endothelial dysfunction, and other
novel risk factors may help to better judge the interaction
among all risk factors and atherosclerosis.
Fifth, atherosclerosis is a systemic disease. The
Framingham study21 showed that patients presenting myo-
cardial infarction, cerebral vascular accident, heart failure,
or peripheral vascular insufficiency as their first manifes-
tation would, in the following 10 years, manifest disease
in another vascular territory in proportions varying from
16% to 50%, both for men and women. In addition, sec-
ondary prevention studies with statins have systematically
documented reductions of cardiac events, as well as reduc-
tions in stroke and intermittent claudication; this clinical
observation makes biological sense since the basic patho-
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physiological mechanisms of atherosclerosis are the same,
although regional variations are noted due to specific char-
acteristics of the particular vascular beds. This feature of
atherosclerosis makes it possible to analyze peripheral ves-
sels, such as the carotid and brachial arteries, and draw
meaningful inferences regarding what may occur in the
coronary circulation, as has been shown for endothelial
function22 and carotid intima-media thickness.23
Noninvasive vascular analysis has taken advantage of this
fact, as will be discussed later.
So far, the most frequently used method to predict risk
has been the Framingham score24,25 and the European risk
score.26 These take into account the presence of classic risk
factors, EKG findings, and pertinent clinical data. Although
of great practical value, these systems are destined to pre-
dict risk, not the presence of disease in itself. In addition,
since a considerable number of patients do not exhibit clas-
sic risk factors, this subset of individuals is not properly
investigated. In addition, the presence of risk factors by it-
self does not mean that any given individual will develop
the disease. Also, a long time lag between the documenta-
tion of a risk factor and the actual appearance of disease
may occur; for instance, if the time lag is long, treating a
patient for the presence of only 1 or 2 risk factors may in-
deed represent a significant decision problem. Hence, the
search for methods of early detection of coronary disease
may be justified. When the disease is detected in its early
phases, a customized treatment may be proposed. But if
no disease is present, the aggressive treatment of 1 risk fac-
tor may not be justified. Hence, an individualized approach
should be aimed at, for; it would allow safer and eventu-
ally less costly treatments.
NONINVASIVE DETECTION OF
ATHEROSCLEROSIS
Clinical information is highly relevant for the recogni-
tion of atherosclerosis; thus, the typical history of angina,
intermittent claudication, or a past coronary event, such as
myocardial infarction, indicates with great probability the
presence of the disease. The Framingham study27 estab-
lished the validity of hypercholesterolemia, smoking, age,
male sex, diabetes, obesity, sedentariness, and arterial hy-
pertension, among others, as major determinants of future
cardiovascular events, as to be later discussed. Diabetes in
particular has received special recent attention,28 since its
mere presence has been found to be as strong a predictor
of events as a previous myocardial infarction. In parallel,
the metabolic syndrome represented by insulin resistance,
obesity, hypertension, and atherogenic dyslipidemia repre-
sents a major cause of atherosclerosis.29
Physical examination is very often entirely normal in
atherosclerotic individuals, especially in the early phases
of the disease. However, some findings, such as a carotid
murmur or the absence of peripheral pulses, carry a strong
predictive power.
Some specific laboratory data have predictive value for
atherosclerosis development. Hypercholesterolemia, specifi-
cally elevated low-density lipoprotein, is the best known and
also the most widely tested lipid abnormality in primary and
secondary prevention studies.30  It is worth considering low-
density lipoprotein heterogeneity. Small, dense low-density
lipoprotein particles are more atherogenic than large, buoy-
ant low-density lipoprotein particles.31 The oxidation of low-
density lipoprotein also increases its atherogenicity. Low-
density lipoprotein contains apolipoprotein (apo) B-100,
which may be also atherogenic. Furthermore, some particles
are larger and rich in triglycerides (large very-low-density
lipoprotein), whereas others are smaller and rich in
cholesteryl esters (small very-low-density lipoprotein, inter-
mediate-density lipopoprotein). It is now known that rem-
nant lipoproteins containing apo C-III are highly atherogenic,
as is lipoprotein(a), another member of the apo B-100
group.32 Based on numerous large and well-designed clini-
cal trials that followed thousands of patients for many years,
it can be said that the benefits of lipid lowering therapy are
now demonstrated beyond any reasonable doubt. These ben-
efits extend to both men and women of all ages.30
Low levels of high-density lipoprotein are also recog-
nized as an independent risk factor.33 We have shown that
in healthy individuals in whom the only abnormality was
a low level of high density lipoprotein, the endothelial-de-
pendent arterial relaxation was significantly impaired and
that this alteration could be reversed by niacin treatment.34
These individuals also had a decreased plasma clearance
of chylomicron remnants; the two abnormalities facilitate
atherosclerosis development and may explain the known
elevated susceptibility for early atherosclerosis of patients
with low levels of high-density lipoprotein.
Hypertriglyceridemia has also been analyzed. Accord-
ing to a meta-analysis of 17 prospective trials, hypertri-
glyceridemia is an independent risk factor for cardiovas-
cular disease.35 The PROCAM study for instance found a
significant relationship between hypertriglyceridemia and
coronary artery disease risk, independent of low- and high-
density lipoprotein levels.36
Remnant lipoproteins derived from chylomicrons and/
or very low-density lipoprotein also promote atherogenesis
and correlate especially with the progression of atheroscle-
rosis.37 Both remnant cholesterol and remnant triglycerides
were found to be increased in diabetic men and women
compared with nondiabetics.38
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We have also analyzed the triglycerides/high-density li-
poprotein ratio in relation to the precocity of coronary ar-
tery disease detection in 495 patients with documented
coronary artery disease.39 Taking triglycerides of 150 mg/
dL and high-density lipoprotein of 40 mg/dL as normal val-
ues, a triglycerides/high density lipoprotein ratio of 3.75
was reckoned to be a normal value  39It was subsequently
shown that values above 4.0 coincide with higher propor-
tions of small low-density lipoprotein particles in human
plasma,40 which have already been demonstrated to be par-
ticularly atherogenic. Although all lipid variables were as-
sociated with coronary artery disease, the strongest asso-
ciations were with triglycerides and the triglycerides/HDL
ratio above 3.75, especially in patients younger than 50
years of age. In addition, we found in 274 patients sub-
jected to diagnostic coronary angiography that the extent
of coronary disease evaluated through the Friesinger score41
best correlated with the triglycerides/high density lipopro-
tein ratio.42 Thus, a triglyceride/high density lipoprotein
ratio > 4.0, not only correlates with precocity of coronary
artery disease as clinically detected but also with more ex-
tensive coronary lesions. It may hence be a useful surro-
gate for atherosclerosis assessment.
Less commonly used, lipoprotein(a) may also be of value.
Lipoprotein(a) is structurally similar to low density lipopro-
tein in protein and lipid composition.32 Retrospective case-
control studies found a strong association between elevated
lipoprotein(a) levels and coronary artery disease; however
it should be noted that only 9 out of 13 prospective studies
found lipoprotein(a) to be an independent risk factor for coro-
nary artery disease. There is no clinical trial demonstrating
that lowering lipoprotein(a) levels decreases coronary artery
disease risk. Thus the value of lipoprotein(a) for atheroscle-
rosis prediction remains uncertain.
NEW RISK FACTORS FOR ATHEROSCLEROSIS
The inflammatory nature of atherosclerosis may be evi-
denced through  easily measurable plasma components that
can be, and have been proposed to reflect not only the pres-
ence of the disease itself, but also to indicate its clinical
course, complications, and prognosis.43-50 High sensitivity
C-reactive protein is the most used of these parameters. It
has –additive value for predicting coronary artery disease
risk beyond the classic risk factors.43 In prospective stud-
ies, healthy men and women with increased baseline lev-
els of C-reactive protein were at increased risk for future
coronary artery disease.44 Subclinical coronary calcification
was also associated with increased C-reactive protein, in
men and women45 and was significantly elevated in patients
with coronary disease who died suddenly. It also correlates
with immunohistochemical staining intensity and numbers
of inflammatory cells in thin cap atheroma.46 Furthermore,
one study reported that C-reactive protein is a risk factor
that is independent of traditional risk factors, such as total
cholesterol, high density lipoprotein cholesterol, age, smok-
ing, body mass index, and blood pressure in women.47 A
proof of concept argument can be the results of lipid-low-
ering trials in patients with recent acute coronary syn-
dromes. In the PROVE-IT48 study, patients with a recent
myocardial infarction were treated with either pravastatin
or atorvastatin and followed up for a mean of 24 months;
regardless the statin used. The reductions in recurrent myo-
cardial infarction were greater when low-density lipopro-
tein < 70 mg/dL and C-reactive protein < 2 mg/L were
achieved simultaneously by statin therapy than when those
two values were above such limits. When low-density li-
poprotein was <70 mg/dL but C-reactive protein >2 mg/L,
or vice-versa, an intermediate reduction in recurrent myo-
cardial infarction was observed. Thus lowering lipid lev-
els and combating inflammation, both resulting from statin
therapy, are comparably important for prevention of com-
plications post acute coronary events.
A caveat regarding the routine use of C-reactive protein
for risk prediction is warranted. C-reactive protein is a non-
specific marker of inflammatory diseases: it can be elevated
in practically every inflammatory disease, such as rheumatic,
chronic bacterial, or immunologic conditions. Nevertheless,
the optional use of C-reactive protein to guide physicians in
identifying patients without known cardiovascular disease
who may be at higher risk than estimated by major risk fac-
tors alone was recently recommended by the American Heart
Association.49 The rationale is that the additional informa-
tion may guide the clinician in deciding for further evalua-
tion, such as functional tests or even therapy.
Lipoprotein-associated phospholipase A2 has been stud-
ied. Lipoprotein-associated phospholipase A2 is an enzyme
that catalyzes the hydrolysis of oxidized phospholipids,
generating 2 bioactive products that can potentiate athero-
genesis: lysophosphatidylcholine and nonesterified fatty
acid moieties.3,4 Examining the association of lipoprotein-
associated phospholipase A2 mass and activity with calci-
fied coronary plaques in 266 cases of young adults and
comparing to 266 controls, the authors of the Cardia study51
found that lipoprotein-associated phospholipase A2 was sig-
nificantly higher in the cases than in the controls. They con-
cluded that the enzyme is a useful marker for subclinical
cardiovascular risk. Further studies are necessary, but li-
poprotein-associated phospholipase A2 is a potential thera-
peutic target.
Homocysteine is the product of demethylation of me-
thionine; remethylation and trans-sulfuration are critical
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steps in its degradation. Hyperhomocysteinemia is gener-
ally considered a contributing factor in systemic atheroscle-
rosis, cerebrovascular disease, and peripheral vascular dis-
ease. Several case-control and cohort studies have linked
hyperhomocysteinemia with coronary artery disease risk.
In a Brazilian population of 236 patients, men and women,
subjected to diagnostic coronary angiography, we recorded
a number of significant points: (i) homocysteine levels were
higher in those with than in those without coronary artery
disease; (ii). multivariate analysis showed hyperhomo-
cysteinemia to be an independent risk factor for coronary
artery disease with an odds ratio of 2.48 (CI 95% 1.02-
6.14); (iii) an inverse relationship between homocysteine
levels and folic acid was observed; (iv) patients with more
advanced coronary lesions as determined by the Friesinger
method had a higher frequency of hyperhomocysteinemia.52
Our data are consistent with other studies, such as the
Framingham Heart Study53 and the Atherosclerosis Risk in
Communities (ARIC) study.54.
B-TYPE NATRIURETIC PEPTIDE
Natriuretic peptides are hormones involved in volume
homeostasis and have been found to be increased in ven-
tricular dysfunction. There are suggestions that they may
have prognostic significance in apparently healthy persons.
Thus, in 3,346 persons without heart failure included in the
Framingham Heart Study, plasma B-type natriuretic pep-
tide and N-terminal pro-atrial natriuretic peptide were ex-
amined regarding (a) the risk of death from any cause, (b)
a first major cardiovascular event, (c) heart failure, (d) atrial
fibrillation, (e) stroke or transient ischemic attack, and (f)
coronary heart disease.55 Even adjusting for cardiovascu-
lar risk factors, each increment of one standard deviation
in B-type natriuretic peptide levels was associated with a
27% increase in the risk of death (P < .009), a 28% in-
crease in the risk of a first cardiovascular event (P < .03),
and a 77% increase in the risk of heart failure (P < .001).
The mean follow-up was 5.2 years. The investigators con-
cluded that plasma B-type natriuretic peptide levels pre-
dict the risk of death and cardiovascular events independ-
ent of traditional risk factors.55,56 Further studies are needed
to establish the true value of this parameters in terms of
risk prediction in asymptomatic individuals.
SOLUBLE CD40 LIGAND
The CD40-CD40 ligand system is present in leukocytic
and nonleukocytic cells, including endothelial and smooth-
muscle cells and on activated platelets.57 The CD40 ligand
also occurs as soluble CD40 ligand (sCD40L), which is
proinflammatory for endothelial cells and promotes tissue
factor expression on monocytes and endothelial cells. Evi-
dence indicates that the CD40 ligand plays key roles in
atherosclerosis development, progression, and complica-
tions, even in apparently healthy individuals. For instance,
the Orbofiban in Patients with Unstable Coronary Syn-
dromes—Thrombolysis In Myocardial Infarction-16
(OPUS-TIMI-16) found that elevated plasma levels of
sCD40L identify patients at increased risk of death and re-
current myocardial infarction independent of other predic-
tive variables, including troponin I and C-reactive protein.58
Additional investigation is warranted to define the prac-
tical role of soluble CD40 ligand in primary prevention.
FRAMINGHAM RISK SCORE
The Framingham risk score is certainly very popular and
useful. It is a global risk score based on traditional risk fac-
tors such as age, sex, smoking, blood pressure, diabetes, ar-
terial hypertension, and cholesterol values. According to the
Framingham risk score, individuals are ranked into low-, in-
termediate-, and high-risk groups based on their chances of
having events in 10 years. The low-risk group has less than
6% risk over 10 years, the intermediate-risk group, 6% to
20% risk over 10 years, and the high-risk group, equal to or
higher than 20% risk over 10 years. Risk for the latter group
is equivalent to those for patients with stable established
coronary artery disease.59 Greenland et al,59 analyzed the
North American adult population and estimated that 35% are
in the low-risk group, 40% in the intermediate-risk group,
and 25% in the high-risk group. This score system facili-
tates identification of patients at different risk levels and also
has implications for counseling and treatment. The absence
of any major risk factor identifies individuals at very low
risk, while the traditionally major risk factors account for
50% to 80% of subsequent cardiovascular events in high-
risk patients.60,61 The high-risk group—i.e., risk greater than
20% for 10 years—probably benefits from aggressive risk
factor reduction such as a combination of healthy eating and
exercise plus aggressive medical therapy, while patients at
low risk require essentially advice regarding healthy life-
styles. However, the intermediate group represents the great-
est challenge for treatment decisions and should always be
evaluated carefully and individually.62
The European Risk Score25 is based on similar criteria
and is therefore equivalent for practical purposes. A major
limitation of this risk score system is that a significant
number of individuals in the fifth and sixth decade of life
with documented coronary artery disease, perhaps as many
as 40%,20 do not exhibit the traditional risk factors. Accord-
ingly, a modification to this scoring has recently been sug-
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gested aiming to improve coronary artery disease risk as-
sessment in asymptomatic people. It is conceivable that the
use of serum biomarkers, especially C-reactive protein and
atherosclerosis imaging, including coronary calcium scor-
ing or carotid ultrasound for intima-media thickness, may
refine risk estimation.
DETECTION OF MYOCARDIAL ISCHEMIA
There are several ways to detect myocardial ischemia
by noninvasive methods in addition to clinical data as men-
tioned before. Although several diseases, such as congeni-
tal coronary anomalies, myocardial hypertrophy, and
tumors, can cause myocardial ischemia, by far the most
common cause is atherosclerosis. Therefore, in suscepti-
ble patients, the detection of myocardial ischemia usually
implies atherosclerosis as the underlying disease. Germane
to this scenario is the premise by which any noninvasive
test should be interpreted.
 According to the Bayes’ theorem, the greater the preva-
lence of the disease in the population to which an individual
belongs, the greater the validity of a positive test and like-
lihood that this is a true positive. Hence, in any popula-
tion where there is a low likelihood of the condition being
present, a positive result has limited value, being more
likely a false positive.63
RESTING AND EXERCISE STRESS TESTING
Resting EKG is of limited value for ischemia recogni-
tion, since more often than not, it is normal. However, some
specific findings are of great significance, such as signs of
previous myocardial infarction, ST depression, and T wave
inversion.
Conversely, stress EKG testing, either pharmacological
or exercise based, is of considerable value and has been
extensively studied in different populations; specific crite-
ria for test interpretation have been developed based on
comparative evolutive data. It is noteworthy that the ma-
jority of positive stress tests are false positives in unselected
asymptomatic people63 because of the low pre-test prob-
ability of disease. Hence, the absolute risk of cardiac events
in these populations remains low; consequently, the rou-
tine use of exercise ECG testing in completely unselected
asymptomatic populations is not recommended. In contrast,
a positive exercise test in middle-aged men with several
coronary risk factors has independent predictive power for
major coronary events. On the other hand, even in the pres-
ence of risk factors, the predictive power of a positive test
is not the same for women and young adults because dis-
ease prevalence is low.63
RESTING AND STRESS ECHOCARDIOGRAPHY
Myocardial ischemia or infarction typically cause seg-
mental myocardial dysfunction that can be detected by a
2-dimensional echocardiogram at rest. Areas of wall mo-
tion abnormalities, wall thinning, aneurysms, global ven-
tricular dilation, increased ventricular volumes, and de-
creased ejection fraction can be indirect indicators of myo-
cardial ischemia or necrosis. Given the ease with which an
echocardiogram can be obtained, this method has consid-
erable practical application in individual patients, especially
those in whom exercise stress tests can not be performed.
Stress echocardiography is based on the principle that
acute, induced myocardial ischemia leads to left ventricu-
lar dysynergy. It should be considered that the test adds
costs and complexity to the exam. In a meta-analysis of
28 studies, the sensitivity and specificity of dobutamine
stress echocardiography was 80% and 84%, respectively,
for detection of coronary artery disease.64 In addition, there
is only limited data supporting the use of stress
echocardiography as a tool to assess the intermediate-risk
patient.65 However, stress echocardiography can be of value
in certain patients in the intermediate-risk category, such
as women and the elderly. Additional studies are needed
to define its role for elevating such patients to the high-
risk category for primary prevention.
EXERCISE AND PHARMACOLOGICAL
MYOCARDIAL PERFUSION IMAGING
Myocardial perfusion scintigraphy is one of the most use-
ful, widely used, and reliable methods for noninvasive myo-
cardial ischemia detection or elimination. It also has a unique
position as a tool for myocardial viability analysis. Its sensi-
tivity is about 95%, and its specificity reaches close to 90%
in large series;66 its high negative predictive value of about
98% in asymptomatic individuals is of significant practical
usefulness. Whether or not stress thallium scintigraphy can
be a useful addition to exercise ECG testing for determining
risk for major coronary events in intermediate-risk asympto-
matic patients remains a critical question. Limited data sug-
gest incremental value for this purpose in some populations,
such as postmenopausal women and elderly men (age > 75
years) in whom the use of exercise ECG testing is of limited
applicability. Recently, Lima et al67 reported stress SPECT re-
sults in 328 patients aged 74 years or older. Abnormal results
were common, particularly in men, in patients with chest pain,
and in those with resting or exercise ST-T abnormalities. Pa-
tients with normal perfusion images had an annual hard event
rate of < 1.0% per year, while those with abnormal images
had a corresponding annual rate of 14.3% per year.
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Because few prognostic studies have included adequate
numbers of asymptomatic people, data are scarce regarding
the prognostic utility of noninvasive measures for the detec-
tion of myocardial ischemia in apparently asymptomatic peo-
ple. With the exception of exercise ECG testing in asympto-
matic men with increased cardiovascular risk profiles, few data
exist to support the use of the noninvasive testing modalities.64
DIRECT DETECTION OF ATHEROSCLEROTIC
PLAQUE
Duplex ultrasound
Duplex ultrasound is widely applicable for the early
detection of atherosclerosis in the noninvasive vascular
laboratory. Its major advantages include the simplicity and
general availability of the procedure. Examination of the
carotid arteries to measure the intima-media thickness is
used routinely, and evaluation of plaques and even estimates
of the degree of obstruction also are performed on a regu-
lar basis. Although plaque diameter is readily measurable,
the variable and complex 3-dimensional morphology of
plaques68 produces a poor correlation with actual plaque size
or volume. Semiquantitative approaches include averaging
of plaque diameters; the number of segments with plaques
in the common carotid artery, bulb, internal carotid artery,
and external carotid artery; or plaque number. Intima-me-
dia thickness correlates well with the extent of coronary
lesions, and furthermore, as intima-media thickness in-
creases, cardiovascular event rates also increase.68,69 Thus,
in the Kuopio Ischemic Heart Disease Risk Factor Study,
myocardial infarction risk increased by 11% for each 0.1
mm increase in common carotid intima-media thickness.70
Measurement of the ankle-brachial index with a
handheld continuous-wave Doppler instrument is an accu-
rate way to diagnose peripheral arterial disease. This is im-
portant not only for identifying patients with peripheral ar-
terial disease but also because they frequently have athero-
sclerosis in other arterial territories and hence may have
increased frequency of myocardial infarction and stroke.71
Duplex ultrasound may also be used to assess brachial
artery reactivity, and therefore, endothelial function.22,72 As
shown by Celermajer et al,21 brachial artery reactivity ac-
curately reflects coronary reactivity and therefore can be
used as a surrogate marker of coronary endothelial func-
tion. Endothelial dysfunction actually precedes clinical
manifestations of coronary artery disease, is a better prog-
nostic indicator of events than coronary lesions themselves,
is associated with several risk factors, and can be improved
by the correction of many classic risk factors such as
hypercholesterolemia and arterial hypertension.73 However,
long-term studies of endothelial function are still necessary
to prove its relationship to coronary atherosclerosis and its
value as predictor of events in asymptomatic individuals.
ULTRA FAST COMPUTED TOMOGRAPHY –
DETECTION OF THE AMOUNT OF CALCIUM
Fast imaging is essential to overcome cardiac and respi-
ratory motion artifacts; ultra fast computed tomography does
just that. Only electron-beam computed tomography74 and
fast-gated helical or spiral computed tomography75 can meas-
ure the amount or volume of calcium in blood vessels, al-
though magnetic resonance imaging, x-ray angiography, and
ultrasound can also identify calcified deposits in vessels.
Atherosclerotic calcification may occur in early atheroscle-
rotic lesions, it but is found more frequently and more ex-
tensively in advanced lesions.76 An association between coro-
nary calcium and coronary artery disease has been docu-
mented;, there is also evidence that the amount of coronary
calcium is a predictor of risk of coronary events.77 Accord-
ing to a meta-analysis of data in asymptomatic populations,
a calcium score above the population median value was as-
sociated with an unadjusted odds ratio of 4.2 (95% confi-
dence interval [CI] 1.6 to 11.3) for myocardial infarction or
death.78 It is not certain, however, whether the predictive
value of coronary calcification in high-risk subjects is supe-
rior to that of standard coronary risk factors79; given the cost
and complexity of the test, this is a point of considerable
practical interest. The additional benefit of using both coro-
nary artery calcium scores plus the Framingham risk score
was evaluated by Greenland et al80 in 1,461 asymptomatic,
middle-aged (> 45 years) adults with at least 1 coronary risk
factor; they were followed for 8.5 years after the computed
tomography scan. A coronary artery calcium score > 300 was
predictive of myocardial infarction or coronary death; (P <
.001), compared with a score of zero. Moreover, coronary
artery calcium scores were predictive of risk among patients
with a Framingham risk score higher than 10% (P < .001)
but not with a Framingham risk score lower than 10%, sug-
gesting that high coronary artery calcium scores can modify
the predicted risk obtained from Framingham risk score
alone, especially among patients in the intermediate-risk cat-
egory.79 Figure 1 illustrates calcium scoring.
CONTRAST-ENHANCED NONINVASIVE
CORONARY ANGIOGRAPHY
Noninvasive coronary angiography is performed after
the intravenous administration of iodinated contrast agent,
with EKG synchronization and during breath holding to
minimize motion artifacts. Multiplanar reformat, maximum
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intensity projection, volume rendering, or virtual
angioscopy can be performed and aid in the diagnosis of
coronary stenosis. The technique is improving rapidly, and
the newer generation 64-slice multidetector computer to-
mography will further refine diagnostic capability. Sensi-
tivities of 89% to 92% and specificities of 93% to 98% have
been recently reported, after the exclusion of arteries con-
sidered to be of subdiagnostic image quality.81,82
Although the diagnostic accuracy of noninvasive angi-
ography regarding the degree of stenosis is still a matter
of concern, this method may be satisfactory and conven-
ient after percutaneous or surgical revascularization. Indeed,
some studies show good results in detecting total occlu-
sions but rather low sensitivity and specificity for identi-
fying in-stent restenosis or saphenous vein graft lesions.83,84
The detection of noncalcified atherosclerotic plaques
prone to rupture by computed tomography has also been
tried with promising results.85,86 However, multidetector
computed tomography underestimates plaque burden when
compared to intravascular ultrasound, probably due to lower
spatial resolution, especially in distal segments.87 Long-
term observations regarding the predictive value of
multidetector computed tomography are not available be-
cause of its relatively recent development; however, given
its noninvasive nature and overall diagnostic precision, pro-
gressive use can be anticipated in the near future.
MAGNETIC RESONANCE IMAGING
Cardiac magnetic resonance imaging offers a unique,
impressive range of information that has revolutionized the
field of cardiac imaging. Through cardiac magnetic reso-
nance, the dynamics of cardiac function can be appreci-
ated in minute detail, and pathophysiological mechanisms
became evident, forming the basis for clinical or surgical
management of patients with known or suspected coronary
artery disease. Cardiac magnetic resonance methods allow
assessment of global and regional cardiac function, cardiac
volumes, myocardial perfusion, cardiac valves, pericar-
dium, myocardial viability, and proximal coronary
anatomy, among others. Individually, these methods have
shown promise as alternatives to the established tools for
the noninvasive detection of coronary stenosis and myo-
cardial infarction.88-90 A unique advantage of cardiac mag-
netic resonance imaging is that several of its methods can
be combined in a single scanning session.
CONTRAST-ENHANCED MAGNETIC
RESONANCE ANGIOGRAPHY
Noninvasive, accurate detection of coronary stenosis has
been a challenge for quite some time. Recently, contrast-en-
hanced coronary magnetic resonance angiography was found
to have high specificity and sensitivity compared with x-ray
angiography for the detection of luminal narrowing > 50%
in humans.89 Technical advances in processing speed and new
contrast agents91,92 are partly responsible for the rapid evo-
lution of the field. Imaging of large vessels, such as the aorta,
carotid, and femoral arteries, is now routine and replaces con-
ventional angiography, with unquestionable advantages. In
addition, contrast-enhanced magnetic resonance angiography
methodology has been proposed as a technique for the as-
sessment of coronary anomalies, patency of bypass grafts,
post-stent improvement in coronary flow, and coronary in-
stent restenosis.93-97
HIGH-RESOLUTION MRI FOR PLAQUE
CHARACTERIZATION
Plaque destabilization is responsible for acute coronary
syndromes and is a complex phenomenon characterized by
inflammation, thrombosis, apoptosis, hemorrhage, and en-
dothelial dysfunction that occur mostly in lipid-rich
plaques. Magnetic resonance can differentiate plaque com-
ponents with reasonable accuracy, based on biophysical and
biochemical parameters such as chemical composition,
water content, physical state, molecular motion, or diffu-
sion.57 Thus far, magnetic resonance plaque characteriza-
tion of the carotid arteries and aorta has proven to be very
sensitive and specific as compared to that of the coronary
arteries.98,99 A crucial ultimate goal of cardiovascular
Figure 1 - Ultra fast multislice computer tomography of coronary arteries.
Calcification of coronary, score 9.8 Agatston,80 75th percentile for age and
gender
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noninvasive imaging is to have reliable technology for
plaque characterization of the coronary arteries.56
Magnetic resonance imaging is a new noninvasive
method that can detect morphologic characteristics of coro-
nary arteries in vivo in animals and humans and also allows
the identification of arterial remodeling in experimental
atherosclerosis.100-103 We have already detected by magnetic
resonance imaging coronary vessel wall modifications, e.g.,
increases in wall thickness, vessel wall area, and total ves-
sel area in patients with coronary artery disease compared
to normal controls.104 Interestingly, the luminal area was pre-
served in these patients in spite of the presence of large
plaque volumes (Figure 2). Thus, magnetic resonance
imaging to determine the luminal area/total vessel area ra-
tio is a noninvasive method for detecting coronary vessel wall
modifications including remodeling and for clearly differ-
entiating patients with coronary artery disease from healthy
subjects despite a similar lumen (Figures 3a, 3b).
IDENTIFYING THE UNSTABLE PATIENT
The relationship between risk factors and the occurrence
of atherosclerosis is unpredictable and variable. In general,
it takes decades for risk factors to cause significant vessel
obstruction and clinical syndromes. Although risk factors,
and especially the clustering of 2 or more, will eventually
lead to obstructive lesions, the time course of such events
in any individual patient is far from predictable. Thus, some
patients may have a slow clinical course over decades and
finally present with typical effort angina due to flow-lim-
iting stenosis, often affecting all coronary beds. On the
other extreme, patients may present with acute coronary
syndromes in their forties and fifties, with coronary lesions
of moderate severity or even minor stenosis, due to
destabilization of the plaque. Clearly then two different
challenges must be faced if prevention of lesions on one
hand and prevention of events on the other are to be
Figure 3a - Magnetic resonance of coronary arteries. Positive remodeling of coronary arteries indicated by increased wall thickness, wall area, and total
vessel area with preservation of luminal area104
Figure 2 - Magnetic resonance of coronary arteries. Observe the increment of wall thickness and total vessel diameter of diseased vessel, a positive
remodeling (right) compared to the control (left)104
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achieved. Prevention of atherosclerosis development, the
so-called primary prevention, is based on the recognition
of risk factors and early identification of incipient lesions.
For those individuals, the approaches for early detection
of atherosclerosis were examined above. They need long-
term preventive measures directed at controlling risk fac-
tors, such as recommendations for healthy lifestyles and
eventually drug therapy, such as statins, aspirin,
antihypertensives, or treatment for diabetes.
Identifying the unstable patient is an entirely different
matter, because not everyone who has a plaque will soon
have an event; conversely patients with even minor plaques
may suffer acute events. For instance, analyzing 516 pa-
tients who were on a waiting list for coronary surgery, we
observed that the most powerful indicators of complications
in this period were angina, heart failure, and high triglyc-
eride levels; coronary anatomy by itself was not a good pre-
dictor.105 This suggests that functional status, more than
anatomy, is a fundamental determinant of prognosis.
In this regard, the challenge is to identify the unstable pa-
tient. Although inflammatory markers, coronary calcium scor-
ing, magnetic resonance imaging, optical coherence tomog-
raphy, angioscopic studies, thermography studies, and vascu-
lar ultrasonography have all been studied regarding their ability
to identify such vulnerable patients, this still remains an elu-
sive goal.106 Identification of “soft” plaques by noninvasive
means would be critical. In this respect, magnetic resonance
imaging is likely to have the greatest potential. Plaque analy-
sis based on nanoparticles or gadolinium-tagged molecular
imaging is being tested in noncoronary vascular beds, such
as the distal aorta.107,108 Given the velocity of recent develop-
ments in this field, it may not be unrealistic to say we are in
the dawn of the molecular plaque imaging era, which hope-
fully will improve our predictive ability.
These future developments will perfect our ability to
identify not only incipient atherosclerosis but the vulner-
able patient as well; then a more individualized approach
for patient care can be adopted.
RESUMO
Luz PL da, Bertini PJ, Favarat D. Métodos não invasivos
para identificação da doença aterosclerótica - desafios para
prevenção da doença e eventos clínicos. Clinics.
2005;60(5):415-28.
A aterosclerose é uma doença inflamatória crônica que afe-
ta essencialmente todas as artérias incluindo a aorta,
coronárias, carótidas e artérias periféricas. É a causa prin-
cipal de morte no hemisfério ocidental, devido as síndromes
cardiovasculares, tais como o infarto do miocárdio, insufi-
ciência cardíaca e acidentes cerebrovasculares.
Quantidades enormes de recursos econômicos e humanos
são usadas em tratamentos de suas complicações, inclusi-
ve estudos de imagem, cirurgias coronárias, intervenções
com cateteres, marcapasso e tratamentos médicos. Tratar
complicações, entretanto, são ações a posteriori.
Uma alternativa melhor seria prevenir o desenvolvimento
da aterosclerose, ou pelo menos identificar os pacientes que
tenham risco de eventos agudos e intervir antes de sua ocor-
rência.
O objetivo desta revisão é discutir o valor prognóstico dos
fatores de riscos tradicionais e emergentes, e o papel dos
métodos diagnósticos não invasivos para a doença coronária
- teste de esforço, eco estresse, ultra-sonografia dúplex,
tomografia computadorizada e a ressonância magnética. A
combinação de marcadores biológicos e de métodos não
invasivos, é de grande utilidade na identificação precoce da
doença aterosclerótica. Futuros desenvolvimentos logo aper-
feiçoarão nossa capacidade de identificar o paciente vulne-
rável e nos permitir um manejo mais individualizado.
UNITERMOS: Aterosclerose.  Lípides. Doença
coronária. Testes de diagnóstico. Imagem diagnóstica,
cardiovascular.
Figure 3b - LA/TVA ratio for the right coronary artery (RCA; left) and left
anterior descending artery (LAD; right) of patients (filled columns) and
controls (open columns). The reduced ratio for patients with coronary artery
disease was due to vessel enlargement. *p<0.05
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